| Literature DB >> 28658367 |
Bárbara Heather Lutz1,2, Vanessa Irribarem Avena Miranda1, Andréa Dâmaso Bertoldi1,2.
Abstract
OBJECTIVE: To assess the use of potentially inappropriate medications among older adults.Entities:
Mesh:
Year: 2017 PMID: 28658367 PMCID: PMC5493363 DOI: 10.1590/S1518-8787.2017051006556
Source DB: PubMed Journal: Rev Saude Publica ISSN: 0034-8910 Impact factor: 2.106
Potentially inappropriate medications for the older adults, according to Beers criteria (2012), according to levels 1 and 2 of the ATC classificationa. Pelotas, State of Rio Grande do Sul, Brazil, 2014.
| Levels 1 and 2 of the ATC classification | Potentially inappropriate medications | |
|---|---|---|
|
| ||
| n | % | |
| N – Nervous system (n = 897) | 458b | 48.9b |
| Psycholeptics | 217 | 23.2 |
| Antiepileptics | 113 | 12.1 |
| Psychoanaleptics | 105 | 11.2 |
| Other | 23 | 2.4 |
| M – Musculoskeletal system (n = 316) | 169b | 18.0b |
| Anti-inflammatories and antirheumatics | 107 | 11.4 |
| Muscle relaxants | 62 | 6.6 |
| C – Cardiovascular system (n = 2,481) | 144b | 15.4b |
| Antihypertensives | 47 | 5.0 |
| Cardiac therapy | 47 | 5.0 |
| Calcium channel blockers | 34 | 3.6 |
| Other | 16 | 1.8 |
| A – Alimentary tract and metabolism (n = 1,070) | 117b | 12.5b |
| Medications used in diabetes | 96 | 10.3 |
| Other | 21 | 2,2 |
| Other ATC1 groups (n = 875) | 49b | 5.2b |
|
| ||
| Total | 937c | 100 |
a ATC: Anatomical Therapeutic Chemical Classification System26.
b Values for the categories within the ATC classification.
c We have analyzed 5,651 medications for inappropriate use, of which, 937 were classified as potentially inappropriate according to Beers criteria. The numbers indicated, in parentheses, in each ATC1 group, match what was used by the sample (of the 5,700 medications used by the sample, 61 were missing for some of the information used in the table).
Potentially inappropriate medications for the older adults, regardless of dose or diagnosis, according to Beers criteria (2012), according to levels 2 and 5 of the ATC classificationa. Pelotas, State of Rio Grande do Sul, Brazil, 2014.
| Levels 2 and 5 of the ATC classification | Potentially inappropriate medications, regardless of dose or diagnosis | |
|---|---|---|
|
| ||
| n | % | |
| N05 – Psycholeptics (n = 231) | 209b | 28.6b |
| Diazepam | 48 | 6.6 |
| Alprazolam | 44 | 6.0 |
| Bromazepam | 38 | 5.2 |
| Other | 79 | 10.8 |
| M01 – Anti-inflammatories and antirheumatics (n = 179) | 107b | 14.7b |
| Diclofenac sodium and potassium | 37 | 5.1 |
| Ibuprofen | 13 | 2.1 |
| Nimesulide | 12 | 1.6 |
| Other | 45 | 5.9 |
| N03 – Antiepileptics (n = 143) | 90b | 12.3b |
| Clonazepam | 78 | 10.7 |
| Other | 12 | 1.6 |
| A10 – Medications used in diabetes (n = 409) | 89b | 12.2b |
| Glibenclamide | 88 | 12.1 |
| Other | 1 | 0.1 |
| M03 – Muscle relaxants (n = 65) | 62b | 8.5b |
| Caffeine + paracetamol + diclofenac sodium + carisoprodol | 40 | 5.5 |
| Orphenadrine citrate + metamizole sodium + caffeine | 18 | 2.5 |
| Other | 4 | 0.5 |
| C02 – Antihypertensives (n = 53) | 47b | 6.4b |
| Doxazosin mesylate | 39 | 5.3 |
| Other | 8 | 1.1 |
| N06 – Psychoanaleptics (n = 329) | 38b | 5.2b |
| Amitriptyline hydrochloride | 27 | 3.7 |
| Other | 11 | 1.5 |
| C01 – Cardiac therapy (n = 172) | 26b | 3.6b |
| Amiodarone hydrochloride | 24 | 3.3 |
| Other | 2 | 0.3 |
| Other pharmacological groups (n = 4,049) | 62b | 8.5b |
|
| ||
| Total | 730c | 100 |
a ATC: Anatomical Therapeutic Chemical Classification System26.
b Values for the categories within the ATC classification.
c Among the 937 potentially inappropriate medications, according to the Beers criteria, 730 are considered potentially inappropriate regardless of dose or diagnosis. The numbers indicated, in parentheses, in each ATC2 group, match what was used by the sample (of the 5,700 medications used by the sample, 70 were missing for some of the information used in the table).
Potentially inappropriate medications for the older adults, regardless of dose, dosage, or route of administration, according to Beers criteria (2012). Pelotas, State of Rio Grande do Sul, Brazil, 2014.
| Active ingredient | N used | Inappropriate | |
|---|---|---|---|
|
| |||
| n | % | ||
| Acetylsalicylic acid and associations | 212 | 6 | 3.1 |
| Digoxin | 42 | 21 | 55.3 |
| Spironolactone and associations | 38 | 13 | 39.4 |
| Insulin | 35 | 7 | 21.9 |
| Estrogens | 7 | 5 | 83.3 |
| Doxepin | 0 | - | |
| Reserpine | 0 | - | |
|
| |||
| Total | 334 | 52 | 17.0 |
Missing: 16 ASA + associations, four digoxins, five spironolactones + associations, three insulins, and one estrogen.
Potentially inappropriate medications for the older adults according to diagnoses, according to Beers criteria (2012). Pelotas, State of Rio Grande do Sul, Brazil, 2014.
| Medication* | N used | Inappropriate n | % | Diagnoses involved |
|---|---|---|---|---|
| Fluoxetine hydrochloride | 49 | 17 | 34.7 | History of falls or fractures |
| Diltiazem hydrochloride | 41 | 25 | 61.0 | Heart failure; Chronic constipation |
| Citalopram hydrobromide | 40 | 14 | 35.0 | History of falls or fractures |
| Cilostazol | 39 | 8 | 20.5 | Heart failure |
| Sertraline hydrochloride | 39 | 16 | 41.0 | History of falls or fractures |
| Phenytoin | 27 | 15 | 55.6 | History of falls or fractures |
| Paroxetine hydrochloride | 22 | 13 | 59.1 | History of falls or fractures |
| Escitalopram oxalate | 18 | 7 | 38.9 | History of falls or fractures |
| Verapamil hydrochloride | 10 | 5 | 50.0 | Heart failure; Chronic constipation |
| Sulpiride | 9 | 8 | 88.9 | Dementia/cognitive loss; History of falls or fractures; Parkinson’s disease; Lower urinary tract symptoms; Benign prostatic hyperplasia; Chronic constipation |
| Gabapentin | 8 | 2 | 25.0 | History of falls or fractures |
| Ipratropium bromide | 7 | 2 | 28.6 | Lower urinary tract symptoms; Benign prostatic hyperplasia |
| Carbamazepine | 6 | 2 | 33.3 | History of falls or fractures |
| Tramadol hydrochloride | 6 | 1 | 16.7 | Epilepsy |
| Ranitidine hydrochloride | 5 | 4 | 80.0 | Dementia and cognitive loss |
| Loratadine | 5 | 4 | 80.0 | Dementia and cognitive loss; Lower urinary tract symptoms; Benign prostatic hyperplasia; Chronic constipation |
| Oxybutynin hydrochloride | 4 | 2 | 50.0 | Chronic constipation |
| Isometheptene + dipyrone + caffeine | 4 | 1 | 25.0 | Insomnia |
| Topiramate | 4 | 1 | 25.0 | History of falls or fractures |
| Oxcarbazepine | 3 | 1 | 33.3 | History of falls or fractures |
| Pregabalin | 3 | 1 | 33.3 | History of falls or fractures |
| Meclizine hydrochloride | 2 | 2 | 100 | Dementia and cognitive loss; Lower urinary tract symptoms; Benign prostatic hyperplasia; Chronic constipation |
| Desloratadine | 2 | 1 | 50.0 | Dementia and cognitive loss; Lower urinary tract symptoms; Benign prostatic hyperplasia; Chronic constipation |
| Tiotropium bromide | 1 | 1 | 100 | Lower urinary tract symptoms; Benign prostatic hyperplasia |
| Cimetidine | 1 | 1 | 100 | Dementia and cognitive loss |
| Solifenacin succinate | 1 | 1 | 100 | Dementia and cognitive loss; Lower urinary tract symptoms; Benign prostatic hyperplasia; Chronic constipation |
| Sodium valproate | 1 | 1 | 100 | History of falls or fractures |
|
| ||||
| Total | 357 | 156 | 43.7 | |
* Medications considered as inappropriate regardless of diagnosis are not included in this table. Delirium was not assessed in the questionnaire (potentially inappropriate use with this diagnosis: tricyclic antidepressants, anticholinergics, benzodiazepines, chlorpromazine, corticosteroids, H2-receptor antagonists, meperidine, sedative hypnotics, thioridazine).
Prevalence of potentially inappropriate medications according to Beers criteria (2012), according to demographic and socioeconomic variables, polypharmacy, self-medication, and burden of disease. Pelotas, State of Rio Grande do Sul, Brazil, 2014. (n = 1,451 older individuals)
| Variablea | n | Inappropriate (%) | Crude PR | 95%CI | p | Adjusted PR | 95%CI | p |
|---|---|---|---|---|---|---|---|---|
| Level 1 | ||||||||
|
| ||||||||
| Gender | 0.001b | < 0.001b | ||||||
| Male | 537 | 36.7 | 1 | 1 | ||||
| Female | 914 | 45.7 | 1.25 | 1.10–1.42 | 1.26 | 1.11–1.44 | ||
| Age (years) | 0.001c | 0.016c | ||||||
| 60 to 69 | 756 | 39 | 1 | 1 | ||||
| 70 to 79 | 460 | 45.2 | 1.16 | 1.02–1.32 | 1.11 | 0.97–1.27 | ||
| 80 or more | 230 | 48.7 | 1.25 | 1.07–1.45 | 1.18 | 1.01–1.38 | ||
| Race | 0.028b | 0.004b | ||||||
| White | 1,211 | 43.7 | 1 | 1 | ||||
| Non-White | 236 | 36.4 | 0.83 | 0.71–0.98 | 0.79 | 0.68–0.93 | ||
| Education (years of study) | 0.001c | 0.001c | ||||||
| 11 or more | 316 | 36.1 | 1 | 1 | ||||
| 8 to 10 | 143 | 37.1 | 1.03 | 0.81–1.31 | 1.04 | 0.82–1.32 | ||
| 4 to 7 | 445 | 41.6 | 1.15 | 0.95–1.40 | 1.17 | 0.97–1.41 | ||
| 0 to 3 | 533 | 48.2 | 1.34 | 1.12–1.60 | 1.35 | 1.12–1.62 | ||
| Economy level (ABEP) | 0.043c | 0.979c | ||||||
| A/B | 483 | 38.5 | 1 | 1 | ||||
| C | 720 | 43.1 | 1.12 | 0.97–1.28 | 1 | 0.85–1.18 | ||
| D/E | 169 | 45.6 | 1.18 | 0.98–1.42 | 0.99 | 0.80–1.23 | ||
|
| ||||||||
| Level 2 | ||||||||
|
| ||||||||
| Polypharmacy | < 0.001b | < 0.001b | ||||||
| No | 746 | 23.1 | 1 | 1 | ||||
| Yes | 705 | 62.8 | 2.73 | 2.36–3.14 | 2.29 | 1.93–2.70 | ||
| Self-medication | < 0.001b | < 0.001b | ||||||
| No | 1,369 | 41.1 | 1 | 1 | ||||
| Yes | 82 | 64.6 | 1.57 | 1.33–1.87 | 1.41 | 1.19–1.67 | ||
| Burden of disease | < 0.001c | < 0.001c | ||||||
| No chronic diseases | 109 | 19.3 | 1 | 1 | ||||
| 1 | 200 | 22.5 | 1.17 | 0.73–1.88 | 1.04 | 0.64–1.68 | ||
| 2 | 269 | 33.5 | 1.74 | 1.15–2.62 | 1.34 | 0.88–2.04 | ||
| 3 | 282 | 42.9 | 2.23 | 1.46–3.39 | 1.44 | 0.93–2.23 | ||
| 4 diseases or more | 570 | 57.4 | 2.98 | 1.37–3.06 | 1.64 | 1.09–2.45 | ||
a The variables are grouped into hierarchical levels according to their entry in the model of adjusted analysis. We have kept in the model, only the variables with p < 0.20, ensuring the control for possible confounding factors for the variables of the same level and upper level.
b Wald test for heterogeneity.
c Wald test for linear trend.